Type of information: Research agreement
Company: Sanofi (France) Exscientia (UK)
Therapeutic area: Metabolic diseases
Type agreement: research - R&D - licensing
Action mechanism: bispecific molecule. Bispecific small molecules designed by Exscientia are single compounds with integrated pharmacology against two distinct targets. This offers an innovative strategy to address efficacy challenges. Exscientia has also extended its capabilities to phenotypic-driven drug discovery, where complex disease profiles are addressed.
- • On May 9, 2017, Exscientia announced that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the area of metabolic diseases.
- Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets that could work synergistically and be amenable to Exscientia’s bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.
- Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pass through to Exscientia’s lead-finding platform in order to generate bispecific-small-molecule compounds that can further validate the biological hypothesis. Bispecific small molecules passing all these quality gates may progress to full candidate delivery projects for Sanofi.
- As part of this agreement, Exscientia will be responsible for all compound design, whilst chemistry synthesis will be delivered by Sanofi. Further assays, preclinical experiments and subsequent trials for compounds progressing to the clinic will be managed by Sanofi, where Sanofi exercises the licence option.
- • Commercial terms for this agreement include the payment of research funding in order to identify those target pairs with the best combination of chemical compatibility and strong biological relevance plus further funding for prioritised candidate delivery opportunities. For compounds reaching agreed delivery criteria, a series of milestones covering both non-clinical and clinical may be payable by Sanofi. Finally, any licensed products reaching the market will qualify for recurrent sales milestones. The total amount potentially payable by Sanofi to Exscientia on achieving these milestones is € 250 million.